AUS
NZ
UK
CA
USA
IND
Highlights
- Race Oncology discovers 39 molecules targeting cancer-linked proteins.
- Focus on FTO inhibition, key in cancer RNA regulation.
- Collaboration with Monash University boosts oncology research.
Race Oncology (ASX:RAC) has successfully completed a pivotal drug discovery program, resulting in the identification of 39 unique molecules with the potential to inhibit FTO, a protein strongly linked to cancer progression. This milestone, achieved in collaboration with Melbourne's Monash University, marks a significant leap in RNA epigenetics research, strengthening the position of the ASX healthcare stock in modern oncology advancements.
FTO, known as Fatso or FaT and Obesity-associated protein, regulates m6A RNA levels—a process often deregulated in various cancers. The discovery of molecules capable of binding to and potentially inhibiting FTO opens new avenues for cancer treatment strategies.
Collaborative Efforts and Innovative Screening
To identify these molecules, Race Oncology engaged Monash University's Fragment Platform (MFP) to conduct an NMR-based fragment screen. This advanced technology enables the detection of chemical structures binding to FTO or related ALKBH proteins. These proteins are part of the same family, making them relevant targets for drug development.
The screening process identified 39 novel FTO-binding molecules. The findings were validated through multiple methods, including Nuclear Magnetic Resonance (NMR) techniques and surface plasmon resonance, ensuring robust and reliable results. The achievement provides Race Oncology with new intellectual property (IP) that holds promise for cutting-edge drug development.
Scientific Milestone in Drug Discovery
Race Oncology’s Vice President of Research, Professor Mike Kelso, emphasized the significance of this development. According to Professor Kelso, “Identification of chemical hits that bind to a protein target of interest is a critical step in modern drug discovery.” This discovery positions Race Oncology at the forefront of RNA epigenetics, enhancing its role in the development of innovative cancer therapies.
Market Reaction and Future Prospects
Following the announcement, Race Oncology's shares showed positive movement. At 11:31 AEDT, the stock was trading at $1.40, reflecting a 2.94% increase since the market opened. This upward trend highlights market optimism about the company's advancements in oncology research.
Race Oncology’s success underscores the potential of RNA epigenetics to revolutionize cancer treatment, providing hope for breakthroughs in tackling some of the most challenging cancers.
